keyword
MENU ▼
Read by QxMD icon Read
search

Y90

keyword
https://www.readbyqxmd.com/read/29902521/procholecystokinin-expression-and-processing-in-cardiac-myocytes
#1
REVIEW
Jens P Goetze, Jens F Rehfeld
The mammalian heart is by now an established endocrine organ whose myocytes in a regulated manner release atrial and ventricular natriuretic peptides (ANP and BNP). But like other hormone-producing cells in classic endocrine organs, the cardiac myocytes also express genes of additional peptide hormones. One such hormone gene is that of the well-known pleiotropic gut-brain peptide system, cholecystokinin (CCK), which is expressed at mRNA and protein levels in both atrial and ventricular cardiac myocytes. The posttranslational processing of proCCK in the myocytes, however, deviates substantially from that of other CCK-producing cells...
June 11, 2018: Peptides
https://www.readbyqxmd.com/read/29724061/gastrodoudenal-embolization-indications-technical-pearls-and-outcomes
#2
REVIEW
Gokhan Kuyumcu, Igor Latich, Rulon L Hardman, Gabriel C Fine, Rahmi Oklu, Keith B Quencer
The gastroduodenal artery (GDA) is frequently embolized in cases of upper GI bleed that has failed endoscopic therapy. Additionally, it may be done for GDA pseudoaneurysms or as an adjunctive procedure prior to Yttrim-90 (Y90) treatment of hepatic tumors. This clinical review will summarize anatomy and embryology of the GDA, indications, outcomes and complications of GDA embolization.
May 2, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29448165/-90-y-radioembolization-dosimetry-using-a-simple-semi-quantitative-method-in-intrahepatic-cholangiocarcinoma-glass-versus-resin-microspheres
#3
Nariman Nezami, Nima Kokabi, Juan C Camacho, David M Schuster, Minzhi Xing, Hyun S Kim
INTRODUCTION: There are two different types of 90 Y Microspheres, glass and resin, in the market for 90 Y radioembolization (90 Y-RE). This study aimed to investigate the dose of radiation delivered through glass vs. resin-based 90 Y-RE to intrahepatic cholangiocarcinoma (ICC). METHODS: In this retrospective study, 10 patients with ICC underwent 90 Y-RE, five underwent glass (Glass group) and other 5 resin (Resin group) microspheres. Technetium-99m macro-aggregated albumin (Tc-99m MAA) shunt study was performed two weeks before 90 Y-RE...
April 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29440463/immune-activation-underlies-a-sustained-clinical-response-to-yttrium-90-radioembolisation-in-hepatocellular-carcinoma
#4
Valerie Chew, Yun Hua Lee, Lu Pan, Nurul J M Nasir, Chun Jye Lim, Camillus Chua, Liyun Lai, Sharifah Nur Hazirah, Tony Kiat Hon Lim, Brian K P Goh, Alexander Chung, Richard H G Lo, David Ng, Rene L F Filarca, Salvatore Albani, Pierce K H Chow
OBJECTIVES: Yttrium-90 (Y90)-radioembolisation (RE) significantly regresses locally advanced hepatocellular carcinoma and delays disease progression. The current study is designed to deeply interrogate the immunological impact of Y90-RE, which elicits a sustained therapeutic response. DESIGN: Time-of-flight mass cytometry and next-generation sequencing (NGS) were used to analyse the immune landscapes of tumour-infiltrating leucocytes (TILs), tumour tissues and peripheral blood mononuclear cells (PBMCs) at different time points before and after Y90-RE...
February 13, 2018: Gut
https://www.readbyqxmd.com/read/29413858/abstract-id-247-patient-specific-scatter-reduction-in-sirt-gamma-camera-images
#5
Philipp Matthies, Milad Mesri, Francisco Alves Pinto, Jan Wuestemann, Oliver Grosser
INTRODUCTION: Clinical Bremsstrahlung imaging with gamma cameras or SPECT scanners, for example used in selective internal radiation therapy (SIRT) [1], suffers from low contrast due to a continuous spectrum and a high amount of scatter. Information about the scattering of the radionuclide within the patient's body can be obtained from Monte-Carlo simulations and subsequently being used to improve image quality. METHODS: An MAA-acquisition (CT+SPECT) of a HCC patient with a unifocal uptake in the right liver lobe is segmented (lesion) and loaded into the MC simulation framework GATE [2]...
January 2018: Physica Medica: PM
https://www.readbyqxmd.com/read/29344714/angiographic-anatomy-and-relevance-of-3-and-9-o-clock-arteries-during-radioembolization
#6
Maciej Powerski, Bartosz Bascik, Jazan Omari, Shahen El-Sanosy, Oliver S Grosser, Max Seidensticker, Frank Fischbach, Maciej Pech
PURPOSE: 3 and 9 o'clock arteries (3&9As) which supply the common hepatic duct connect hepatic with duodenal/pancreatic territories. The study purpose is to describe the angiographic anatomy of 3&9As and discuss their relevance when performing radioembolization (RE) of liver malignancies. MATERIALS AND METHODS: The anatomy of the 3&9As was systematically investigated by a retrospective analysis of angiograms, technetium Tc-99 m-macroaggregated albumin (MAA) scintigrams, yttrium-90 (Y90) Bremsstrahlung-SPECT/CT datasets, and clinical data of 153 patients who underwent RE between 2010 and 2013...
January 17, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29329568/prospective-longitudinal-quality-of-life-and-survival-outcomes-in-patients-with-advanced-infiltrative-hepatocellular-carcinoma-and-portal-vein-thrombosis-treated-with-yttrium-90-radioembolization
#7
Minzhi Xing, Nima Kokabi, Juan C Camacho, Hyun S Kim
BACKGROUND: To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS: Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial...
January 12, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29217739/y90-radioembolization-for-locally-advanced-hepatocellular-carcinoma-with-portal-vein-thrombosis-long-term-outcomes-in-a-185-patient-cohort
#8
Nadine Abouchaleh, Ahmed Gabr, Rehan Ali, Ali Al Asadi, Ronald A Mora, Joseph Ralph Kallini, Karen Marshall, Laura Kulik, Samdeep Mouli, Daniela P Ladner, Michael Abecassis, Juan C Caicedo, Ahsun Riaz, Robert J Lewandoski, Riad Salem
Purpose: To report survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with radioembolization (Y90). Methods: With IRB approval we searched our prospectively acquired database for patients treated with Y90 between 2003 and 2017. Inclusion criteria were patients who had advanced stage HCC with tumor PVT. In order to minimize confounding effect, patients with metastases were excluded. Clinical and laboratory data were collected at baseline and 1 month post-Y90...
December 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29194711/institutional-decision-to-adopt-y90-as-primary-treatment-for-hepatocellular-carcinoma-informed-by-a-1-000-patient-15-year-experience
#9
Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B Benson, Mary F Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H Miller, Vahid Yaghmai, Joseph R Kallini, Samdeep Mouli, Robert J Lewandowski
Yttrium-90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival (OS) outcomes in a 1,000-patient cohort acquired over a 15-year period. Between December 1, 2003 and March 31, 2017, 1,000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child-Pugh (CP) class, United Network for Organ Sharing (UNOS), and Barcelona Clinic Liver Cancer (BCLC) staging systems...
December 1, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29181682/effectiveness-of-hepatic-artery-infusion-hai-versus-selective-internal-radiation-therapy-y90-for-pretreated-isolated-unresectable-colorectal-liver-metastases-iu-crclm
#10
Mashaal Dhir, Mazen S Zenati, Heather L Jones, David L Bartlett, M Haroon A Choudry, James F Pingpank, Matthew P Holtzman, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, David A Geller, J Wallis Marsh, Allan Tsung, Amer H Zureikat
BACKGROUND: In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver metastasis (IU-CRCLM) remains unknown. This study sought to compare the overall survival (OS) after HAI versus Y90 for IU-CRCLM patients treated with modern chemotherapy and to perform a cost analysis of both regional methods. METHODS: This study retrospectively reviewed patients receiving HAI or Y90 in combination with modern chemotherapy as second-line therapy for IU-CRCLM...
February 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29147766/pictorial-essay-imaging-findings-following-y90-radiation-segmentectomy-for-hepatocellular-carcinoma
#11
REVIEW
Ronald A Mora, Rehan Ali, Ahmed Gabr, Nadine Abouchaleh, Ali Al Asadi, Joseph Ralph Kallini, Frank H Miller, Vahid Yaghmai, Samdeep Mouli, Bartley Thornburg, Kush Desai, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Transarterial radioembolization is a novel therapy that has gained rapid clinical acceptance for the treatment of hepatocellular carcinoma (HCC). Segmental radioembolization [also termed radiation segmentectomy (RS)] is a technique that can deliver high doses (> 190 Gy) of radiation selectively to the hepatic segment(s) containing the tumor. The aim of this comprehensive review is to provide an illustrative summary of the most relevant imaging findings encountered after radiation segmentectomy. A 62-patient cohort of Child-Pugh A patients with solitary HCC < 5 cm in size was identified...
November 17, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29147442/metastatic-malignant-paraganglioma-a-case-report-and-review-of-literature
#12
Carlo Angelo Prades, Bassel Atassi, Hamid Nazeer
Metastasis is a rare presentation of non-secretory paraganglioma. Consequently, there is no standard of care for the treatment of metastatic malignant paraganglioma. The most widely used chemotherapy regimen for non-resectable cases includes cyclophosphamide, vincristine, and dacarbazine (CVD). CVD has been previously studied with variable therapeutic response. However, yttrium-90 (Y90) radioembolization has not been previously studied in the treatment of hepatic metastasis in patients diagnosed with malignant paraganglioma...
June 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#13
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28875374/yttrium-90-radioembolization-treatment-for-unresectable-hepatocellular-carcinoma-a-single-centre-prognostic-factors-analysis
#14
C Floridi, F Pesapane, S A Angileri, D De Palma, F Fontana, F Caspani, A Barile, A Del Sole, C Masciocchi, G Lucignani, G Carrafiello
The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method...
September 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28812136/clinical-outcomes-of-y90-radioembolization-for-recurrent-hepatocellular-carcinoma-following-curative-resection
#15
Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur, Laura Kulik, Robert J Lewandowski, Riad Salem
PURPOSE: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. METHODS: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed...
December 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28677067/intra-arterial-therapy-of-neuroendocrine-tumour-liver-metastases-comparing-conventional-tace-drug-eluting-beads-tace-and-yttrium-90-radioembolisation-as-treatment-options-using-a-propensity-score-analysis-model
#16
COMPARATIVE STUDY
Duc Do Minh, Julius Chapiro, Boris Gorodetski, Qiang Huang, Cuihong Liu, Susanne Smolka, Lynn Jeanette Savic, David Wainstejn, MingDe Lin, Todd Schlachter, Bernhard Gebauer, Jean-François Geschwind
OBJECTIVES: To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). METHODS: This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014...
December 2017: European Radiology
https://www.readbyqxmd.com/read/28668402/comparative-study-of-post-transplant-outcomes-in-hepatocellular-carcinoma-patients-treated-with-chemoembolization-or-radioembolization
#17
Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Michael Vouche, Rohi Atassi, Khairuddin Memon, Ali Al Asadi, Talia Baker, Juan Carlos Caicedo, Kush Desai, Jonathan Fryer, Ryan Hickey, Michael Abeccassis, Ali Habib, Elias Hohlastos, Daniel Ganger, Laura Kulik, Robert J Lewandowski, Ahsun Riaz, Riad Salem
PURPOSE: To analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC). METHODS: 172 HCC patients who underwent OLT after being treated with transarterial liver-directed therapies (LDTs) (Y90: 93; TACE: 79) were identified. Pre-LDT and pre-OLT clinical/imaging/laboratory characteristics including United Network for Organ Sharing (UNOS) staging and alpha-fetoprotein values (AFP) were tabulated...
August 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28608276/a-comparison-of-yttrium-90-microsphere-radioembolization-to-hepatic-arterial-infusional-chemotherapy-for-patients-with-chemo-refractory-hepatic-colorectal-metastases
#18
COMPARATIVE STUDY
Andrea Cercek, Vyacheslav Gendel, Salma Jabbour, Dirk Moore, Chunxia Chen, John Nosher, Marinela Capanu, Joanne F Chou, Taryn Boucher, Nancy Kemeny, Darren R Carpizo
Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90...
July 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28579675/decision-making-in-interventional-oncology-intra-arterial-therapies-for-metastatic-colorectal-cancer-y90-and-chemoembolization
#19
REVIEW
Alexandra H Fairchild, Sarah B White
Colorectal cancer is the third most common cancer in the United States and the liver is the most common site of metastatic disease. The presence and extent of hepatic metastases are a major prognostic indicator. Although surgical resection is the accepted first-line therapy for colorectal liver metastasis, only 20 to 25% of patients are eligible for resection due to the extent and location of disease. This article discusses the current role of transarterial therapies in the treatment of colorectal liver metastases...
June 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#20
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
keyword
keyword
63897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"